Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications

Kihlberg, Kristina; Baghaei, Fariba; Bruzelius, Maria; Funding, Eva; Holme, Pål André; Lassila, Riitta; Martin, Myriam; Nummi, Vuokko; Ranta, Susanna; Strandberg, Karin; Andersson, Nadine G.; Berntorp, Erik; Astermark, Jan

doi:10.1016/j.thromres.2022.06.015

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The controls with HA were enrolled between 2013 and 2017. In addition to previously reported data, 1,10 information on socioeconomics was registered as well as data on medical history, joint status, comorbidities, replacement therapy and the use of analgesics and antidepressants/anxiolytics. For a fair comparison of quality‐of‐life, persons with current inhibitors were excluded.…”

Section: Methodsmentioning

confidence: 99%

No difference in quality of life between persons with severe haemophilia A and B

et al. 2023

Self Cite

View full text Add to dashboard Cite

Introduction: Good health-related quality of life (HRQoL) is an important goal in the treatment of persons with haemophilia B (PwHB). Studies focusing on this population are limited, however, and data are insufficient.Aim: To assess the HRQoL in PwHB and to compare this to data on persons with haemophilia A (PwHA), as well as to evaluate the impact of joint health on HRQoL and to identify areas of insufficient care. Methods:The B-NORD study enrolled persons with severe haemophilia B and matched controls with haemophilia A. HRQoL was assessed using the EQ-5D-3L questionnaire and joint health using Haemophilia Joint Health Score 2.1 (HJHS).

show abstract

Section: Methodsmentioning

confidence: 99%

No difference in quality of life between persons with severe haemophilia A and B

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…For hemophilia B patients with inhibitors and an allergic reaction/anaphylaxis to factor IX therapy, it is recommended to treat acute bleeds with rFVIIa but is against the use of aPCC as it contains FIX and may cause or worsen an allergic reaction 3 . Also for hemophilia B, the association of ITI protocols with immunosuppressive regimens is an option to achieve the eradication of inhibitors 53,54 .…”

Section: Inhibitorsmentioning

confidence: 99%

Hemophilia throughout the life cycle

Catelli,

Calvache,

Portich

et al. 2023

hcpa

View full text Add to dashboard Cite

Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (hemophilia A) or factor IX (hemophilia B). The continuous improvement of the treatment has made possible to monitor the patient through their life cycle with the inherent transition of care, initially by caregivers in childhood and later by the patient himself. Alterations associated with age added to chronic diseases are a constant challenge in the comprehensive treatment of the patient. One of the main results related to the use of factors VIII and IX is the development of inhibitors, which are IgG alloantibodies directed to exogenous coagulation factors. The likelihood of developing inhibitors varies from one person with hemophilia to another and depends on the interaction between genetic and environmental factors. This review offers a better understanding of the physiological alterations that allow a comprehensive assessment of the patient with hemophilia.

show abstract

Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications

Cited by 2 publications

References 34 publications

No difference in quality of life between persons with severe haemophilia A and B

No difference in quality of life between persons with severe haemophilia A and B

Hemophilia throughout the life cycle

Contact Info

Product

Resources

About